Abstract
Interactions of the tumor necrosis factor superfamily members B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) with their receptors—transmembrane activator and CAML interactor (TACI) and B cell maturation molecule (BCMA)—on B cells play an important role in the humoral immune response. Whereas BCMA is restricted to B cells, TACI is also expressed on activated T cells; we show here that TACI-Fc blocks the activation of T cells in vitro and inhibits antigen-specific T cell activation and priming in vivo. In a mouse model for rheumatoid arthritis (RA), an autoimmune disease that involves both B and T cell components, TACI-Fc treatment substantially inhibited inflammation, bone and cartilage destruction and disease development. Thus, BLyS and/or APRIL are important not only for B cell function but for T cell–mediated immune responses. Inhibition of these ligands might have therapeutic benefits for autoimmune diseases, such as RA, that involve both B and T cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Locksley, R. M., Kileen, N. & Lenardo, M. J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104, 487–501 (2001).
Ashkenazi, A. & Dixit, V. M. Death receptors: signaling and modulation. Science 28, 1305–1308 (1998).
Moore, P. A. et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285, 260–263 (1999).
Shu, H. B. et al. TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J. Leukocyte Biol. 65, 680–683 (1999).
Mackay, F. et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 190, 1697–1710 (1999).
Mukhopadhyay, A., Ni, J., Zhai, Y., Yu, G.-H. & Aggarwal, B.B. Identification and characterization of a novel cytokine, THANK a TNF homologue that activates apoptosis, nuclear factor-kB, and c-Jun NH2-terminal kinase. J. Biol. Chem. 274, 15978–15981 (1999).
Hahne, M. et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J. Exp. Med. 188, 1185–1190 (1998).
von Bulow, G. U. & Bram, R.J. NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science 278, 138–141 (1997).
Laabi, Y. et al. The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed. Nucleic Acids Res. 22, 1147–1154 (1994).
Yan, M. et al. Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity Nature Immunol. 1, 37–41 (2000).
Marsters, S. A. et al. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues TACI and BCMA. Curr. Biol. 10, 785–788 (2000).
Gross, J. A. et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404, 995–999 (2000).
Xia, X. et al. TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B-cell regulation. J. Exp. Med. 192, 137–143 (2000).
Thompson, J. S. et al. BAFF binds to the tumor necrosis factor receptor-like molecule B-cell maturation antigen and is important for maintaining the peripheral B-cell population. J. Exp. Med. 192, 129–135 (2000).
Khare, S. D. et al. Severe B-cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc. Natl Acad. Sci. USA 97, 3370–3375 (2000).
Laabi, Y. & Strasser, A. Lymphocyte survival–ignorance is BLys. Science 289, 883–884 (2000).
Richard, K.G. et al. Attenuation of apoptosis underlies B Lymphocyte Stimulator enhancement of humoral immune response J. Exp. Med. 192, 953–964 (2000).
Hatzoglou, A. et al. TNF receptor family member BCMA (B-cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kB, Elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. J. Immunol. 165, 1322–1330 (2000).
Potocnik, A. J. et al. Expression of activation antigens on T cells in rheumatoid arthritis patients. Scand. J. Immunol. 31, 213–224 (1990).
Wernick, R. M. et al. IgG and IgM rheumatoid factor synthesis in rheumatoid synovial membrane cell cultures. Arthritis Rheum. 28, 742–752 (1985).
Ridley, M. G. Kingsley, G. Pitzalis, C. & Panayi, G. S. Monocyte activation in rheumatoid arthritis: evidence for in situ activation and differentiation in joints. Br. J. Rheumatol. 29, 84–88 (1990).
Thomas, R. Davis, L. S. & Lipsky, P. E. Rheumatoid synovium is enriched in mature antigen-presenting dendritic cells. J. Immunol. 152, 2613–2623 (1994).
Thomas, R. & Quinn, C. Functional differentiation of dendritic cells in rheumatoid arthritis: role of CD86 in the synovium. J. Immunol. 156, 3074–3086 (1996).
Pitzalis, C. Kingsley, Haskard, G. D. & Panayi, G. The preferential accumulation of helper-inducer T lymphocytes in inflammatory lesions: evidence for regulation by selective endothelial and homotypic adhesion. Eur. J. Immunol. 18, 1397–1404 (1988).
Morimoto, C. et al. Abnormalities in CD4+ T-lymphocyte subsets in inflammatory rheumatic diseases. Am. J. Med. 84, 817–825 (1988).
Courtenay, J. S. Dallman, M. J. Dayman, A. D. Martin, A. & Mosedale, B. Immunization against heterologous type II collagen induces arthritis in mice. Nature 283, 665–668 (1980).
Cathcart, E. S. Hayes, K. C. Gonnerman, W. A. Lazzari, A. A. & Franzblau, C. Experimental arthritis in a nonhuman primate. I. Induction by bovine type II collagen. Lab. Invest. 54, 26–31 (1986).
Holmdahl, R. et al. Role of T lymphocytes in murine collagen induced arthritis. Agents Actions 19, 295–305 (1986).
Seki, N. et al. Type II collagen-induced murine arthritis: induction of arthritis depends on antigen-presenting cell function as well as susceptibility of host to an anticollagen immune response. J. Immunol 148, 3093–3099 (1992).
Maini, R. N. et al. Monoclonal anti-TNFa antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol. Rev. 144, 195–223 (1995).
Joosten, L. A., Helsen, M. M., van de Loo, F. A. & van Berg, W. B. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti–TNFa, anti-IL-1 a/b, and IL-1Ra. Arthritis Rheum. 39, 797–809 (1996).
Durie, F. H. et al. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 261, 1328–1330 (1993).
Ware, C. F. APRIL and BAFF connect autoimmunity and cancer. J. Exp. Med. 192, 35–38 (2000).
Acknowledgements
We thank L. Closkey, T. Echevery, R. Pitti, M. Nagel and P. Haas for help with TACI-Fc protein expression and purification and I. Roth for assistance.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Wang, H., Marsters, S., Baker, T. et al. TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol 2, 632–637 (2001). https://doi.org/10.1038/89782
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/89782
This article is cited by
-
Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma
Nature Communications (2023)
-
Advancing Biologic Therapy for Refractory Autoimmune Hepatitis
Digestive Diseases and Sciences (2022)
-
Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells
Nature Biomedical Engineering (2021)
-
Suppressed humoral immunity is associated with dengue nonstructural protein NS1-elicited anti-death receptor antibody fractions in mice
Scientific Reports (2020)
-
Therapeutic effects of a novel BAFF blocker on arthritis
Signal Transduction and Targeted Therapy (2019)